Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q3 2022 · 10-Q
Revenue$366.24K$366.24K−37.7% vs Q3 2021 Net Income-$2.69M-$2.69MN/M vs Q3 2021 EPS Diluted-$0.18-$0.18N/M vs Q3 2021 Gross Profit$47,326−83.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flowderived-$711,080N/M Free Cash Flowderived-$838,437N/M Margins · derivedGross margin12.9%−35.2 pt vs Q3 2021
Operating margin-379.2%−165.2 pt vs Q3 2021
Net margin-735.5%−210.1 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end